Journal Article DKFZ-2025-02559

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Oxford Univ. Press Oxford

Neuro-Oncology nn, nn () [10.1093/neuonc/noaf237]
 GO

Abstract: DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patients. To allow for seamless integration of these complementary models into clinical practice, a practical framework is needed.We leveraged a cohort of nearly 2000 surgically-treated meningiomas with DNA methylation profiling and clinical outcomes data. Existing methylation-based prediction models were dichotomized to yield four risk groups: low and high recurrent risk, each with RT sensitive and resistant subgroups. Risk groups were correlated with progression-free survival in the context of existing biomarkers including extent of resection and WHO grade.We first demonstrated that all risk groups benefit from gross total resection. All 'high-risk, RT sensitive' tumors (n = 306, 15.7%) also benefited from adjuvant RT: after GTR, median PFS increased from 4.68 (4.13-9.48) years to not reached (p = 0.003); after STR, from 2.12 (1.59-3.02) to 4.09 (3.41-not reached) years (p = 0.004). 'Low-risk, RT sensitive cases' (n = 1207, 61.8%) also benefitted from RT after STR (median PFS 7.39 (6.66-12.8) vs. 16.53 (10.35-not reached) years, p = 0.03), suggesting that RT be considered in these patients. Neither 'low-risk RT resistant' (n = 84, 4.3%) nor 'high-risk RT resistant' (n = 356, 18.2%) cases benefitted from RT, and the latter group was associated with universally poor outcomes.We identify methylation-defined risk groups of meningioma for which additional benefit is gained from adjuvant RT, leading to a clinical decision-making framework for straightforward integration of molecular models into clinical practice.

Keyword(s): DNA methylation ; Meningioma ; clinical recommendations ; neuro-oncology ; outcome biomarker

Classification:

Note: epub

Contributing Institute(s):
  1. DKTK Koordinierungsstelle Berlin (BE01)
  2. DKTK Koordinierungsstelle Tübingen (TU01)
  3. KKE Neuropathologie (B300)
Research Program(s):
  1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2025
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Essential Science Indicators ; IF >= 15 ; JCR ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2025-11-20, last modified 2025-11-22



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)